GlassScriptPhysician profile
Catherine Ann Steinkamp
NPI 1730771494
$1,393.98
in general payments reported to CMS, 2019-2025
19 companies · $970 in 2025
The $970 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $35.53 · 2024: $388 · 2025: $970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,375 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,375.13 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $285.49 | 2024-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $173.64 | 2025 | |
| Novo Nordisk INC | $130.11 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Recordati_rare_diseases_inc. | $108.31 | 2024-2025 | Isturisa, Signifor Lar |
| Beta Bionics, INC. | $103.11 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Lilly USA, LLC | $95.06 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.54 | 2025 | Jardiance |
| Neurocrine Biosciences, INC. | $65.36 | 2025 | |
| Cequr Corporation | $61.08 | 2025 | Cequr Simplicity |
| Otsuka America Pharmaceutical, INC. | $54.24 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Amneal Pharmaceuticals LLC | $42.09 | 2025 | Unithroid |
| Xeris Pharmaceuticals, INC. | $36.96 | 2025 | Recorlev, Gvoke Hypopen |
| Madrigal Pharmaceuticals | $29.82 | 2025 | Rezdiffra |
| Rgh Enterprises LLC | $25.44 | 2025 | |
| Soleno Therapeutics, INC. | $24.37 | 2025 | Vykat Xr |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rhythm Pharmaceuticals, INC. | $23.91 | 2025 | Imcivree |
| Tandem Diabetes Care, INC. | $23.26 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Lexicon Pharmaceuticals, INC. | $14.54 | 2024 | |
| Sequel Med Tech, LLC | $13.65 | 2025 | Twiist |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Steinkamp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.